Literature DB >> 25232223

LRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen.

Xin Liu1, Ming-Zhu Huang1, Zhi-Yu Chen1, Xiao-Yin Zhao1, Chen-Chen Wang1, Wei Peng1, Ji-Liang Yin1, Jin Li1, Xiao-Dong Zhu1.   

Abstract

PURPOSE: Wnt pathways control key biological processes that potentially impact on tumor progression and patient survival. The present study analyzed the polymorphism of lipoprotein-related receptor 5 (LRP5) (gene with key functions in Wnt signaling) and its impact on the response to chemotherapy and survival of patients with advanced gastric cancer (AGC).
METHODS: A total of 107 consecutive patients with AGC treated with first-line chemotherapy of EOF regimen were enrolled in the present retrospective study. The association between single nucleotide polymorphism (SNP) of rs3736228 in LRP5 and the clinical outcomes of the patients was studied.
RESULTS: The CC genotype of rs3736228 was significantly correlated with a higher disease control rate when compared to the CT and TT genotypes (89.3% and 61.8%, respectively, P<0.001). A univariate survival analysis also showed that the progression free survival (PFS) and overall survival (OS) for the patients with the TC and TT genotypes of rs3736228 were worse than for the patients with the CC genotype (PFS: 3.3 and 6.7 months, respectively, HR =0.454, P<0.001; OS: 8.1 months and 18.8 months, respectively, HR =3.056, P<0.001). A multivariate Cox model incorporates rs3736228 and clinical features, also identified rs3736228 was significantly associated with the PFS and OS.
CONCLUSIONS: Our results firstly highlight the importance of LRP5 gene of Wnt pathway in the treatment of AGC and identify polymorphism of rs3736228 as independent predictor of disease control rate, PFS and OS in AGC patients treated with first-line chemotherapy of EOF regimen in the Chinese Han population.

Entities:  

Keywords:  Gastric cancer; biomarker; chemotherapy; lipoprotein-related receptor 5 (LRP5); rs3736228

Year:  2014        PMID: 25232223      PMCID: PMC4153929          DOI: 10.3978/j.issn.1000-9604.2014.08.22

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  28 in total

1.  LDL-receptor-related proteins in Wnt signal transduction.

Authors:  K Tamai; M Semenov; Y Kato; R Spokony; C Liu; Y Katsuyama; F Hess; J P Saint-Jeannet; X He
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

2.  The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis.

Authors:  Charlotta Lindvall; Nicole C Evans; Cassandra R Zylstra; Yi Li; Caroline M Alexander; Bart O Williams
Journal:  J Biol Chem       Date:  2006-09-13       Impact factor: 5.157

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Authors:  Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

Review 6.  WNT and beta-catenin signalling: diseases and therapies.

Authors:  Randall T Moon; Aimee D Kohn; Giancarlo V De Ferrari; Ajamete Kaykas
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

7.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

8.  Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling.

Authors:  Bingyu Mao; Wei Wu; Gary Davidson; Joachim Marhold; Mingfa Li; Bernard M Mechler; Hajo Delius; Dana Hoppe; Peter Stannek; Carmen Walter; Andrei Glinka; Christof Niehrs
Journal:  Nature       Date:  2002-05-26       Impact factor: 49.962

Review 9.  Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.

Authors:  Zhen Wang; Jun-qiang Chen; Jin-lu Liu; Xin-gan Qin; Yuan Huang
Journal:  BMC Gastroenterol       Date:  2012-09-29       Impact factor: 3.067

10.  ERCC1 and ERCC2 variants predict survival in gastric cancer patients.

Authors:  Yangkai Li; Zhensheng Liu; Hongliang Liu; Li-E Wang; Dongfeng Tan; Jaffer A Ajani; Qing-Yi Wei
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.